THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.34] ID: TIP-MED-000162

Terbinafine Hydrochloride & Griseofulvin

Active Ingredient / Scientific Identity: Terbinafine Hydrochloride & Griseofulvin • Class: Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inhibitor Dermatophyte Antifungals (Schedule H | NLEM 2022)

⚖️ Compare Profile
Generic / Entity NameTerbinafine Hydrochloride & Griseofulvin ([8.34])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassAllylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inhibitor Dermatophyte Antif
Available Dosage FormsTerbinafine Tablets: 250 mg, 500 mg; Topical Cream: 1%. Griseofulvin Fine-Particle (FP) Microsize Tablets: 125
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Avoid oral Terbinafine if CrCl <50 mL/min (or halve dose to 125 mg OD if essential). Hepatic: Both are contraindicated
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Terbinafine Hydrochloride & Griseofulvin (TIP-MED-000162, Reference Code [8.34]) is classified under Antimicrobials — Systemic Antifungal Agents (Ch 08) as a Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inhibitor Dermatophyte Antifungals (Schedule H | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.34], p. 109): Terbinafine: Sebifin (Sun), Tyza (Abbott), Terbicip (Cipla), Zimig. Griseofulvin: Grisovin FP (GSK), Walavin FP (Wallace), Dermonorm — Strengths & Dosage Forms: Terbinafine Tablets: 250 mg, 500 mg; Topical Cream: 1%. Griseofulvin Fine-Particle (FP) Microsize Tablets: 125 mg, 250 mg, 500 mg
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.34], p. 109): Terbinafine: Sebifin (Sun), Tyza (Abbott), Terbicip (Cipla), Zimig. Griseofulvin: Grisovin FP (GSK), Walavin FP (Wallace), Dermonorm — Strengths & Dosage Forms: Terbinafine Tablets: 250 mg, 500 mg; Topical Cream: 1%. Griseofulvin Fine-Particle (FP) Microsize Tablets: 125 mg, 250 mg, 500 mg
Dosage Forms & Available Strengths:
Terbinafine Tablets: 250 mg, 500 mg; Topical Cream: 1%. Griseofulvin Fine-Particle (FP) Microsize Tablets: 125 mg, 250 mg, 500 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inhibitor Dermatophyte Antifungals (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Systemic Antifungal Agents (Ch 08): clinical efficacy is mediated via Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inhibitor Dermatophyte Antifungals (Schedule H | NLEM 2022) for Terbinafine: First-line fungicidal oral therapy for dermatophytosis (tinea corporis, tinea cruris, tinea pedis) and toenail/fingernail onychomycosis. Griseofulvin: Paediatric Tinea capitis (scalp ringworm).

4. Therapeutic Indications & Evidence-Supported Uses

  • Terbinafine: First-line fungicidal oral therapy for dermatophytosis (tinea corporis, tinea cruris, tinea pedis) and toenail/fingernail onychomycosis
  • Griseofulvin: Paediatric Tinea capitis (scalp ringworm)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Terbinafine (Adults): 250 mg PO Once Daily (or 250 mg BD in recalcitrant dermatophytosis) for 2–4 weeks (Tinea corporis/cruris), 6 weeks (Fingernail), or 12 weeks (Toenail). Griseofulvin FP: Adults: 500–1000 mg PO OD/BD; Children (Tinea capitis): 15–20 mg/kg/day for 6–8 weeks

Administration & Meal Timing: Terbinafine may be taken with or without food; Griseofulvin MUST be taken WITH A HIGH-FAT MEAL or whole milk (doubles GI absorption!) | Once Daily (or BD per specialist protocol)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Avoid oral Terbinafine if CrCl <50 mL/min (or halve dose to 125 mg OD if essential). Hepatic: Both are contraindicated in active liver disease
Elimination & Renal Adjustment:
Renal: Avoid oral Terbinafine if CrCl <50 mL/min (or halve dose to 125 mg OD if essential). Hepatic: Both are contraindicated in active liver disease
Hepatic Impairment Considerations:
Renal: Avoid oral Terbinafine if CrCl <50 mL/min (or halve dose to 125 mg OD if essential). Hepatic: Both are contraindicated in active liver disease

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Terbinafine is CONTRAINDICATED in chronic or active liver disease and severe renal impairment (CrCl <50 mL/min!). Griseofulvin is CONTRAINDICATED in pregnancy (teratogenic; men must also avoid fathering a child during and for 6 months after Griseofulvin!), porphyria, hepatocellular failure, and SLE! Neither is effective against Candida or Pityriasis versicolor!

Key Clinical Precautions: Renal: Avoid oral Terbinafine if CrCl <50 mL/min (or halve dose to 125 mg OD if essential). Hepatic: Both are contraindicated in active liver disease

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Terbinafine: Mild GI upset, headache, rash, reversible loss or distortion of taste (ageusia/dysgeusia). Griseofulvin: Headache, photosensitivity, GI upset
  • Terbinafine: Idiosyncratic severe cholestatic/hepatocellular liver injury (after 2–6 weeks), SJS/TEN, agranulocytosis, subacute cutaneous lupus erythematosus. Griseofulvin: Lupus flare, Disulfiram-like alcohol reaction
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • TERBINAFINE IS A POTENT CYP2D6 INHIBITOR: Markedly increases plasma levels of Tricyclic Antidepressants (Amitriptyline, Nortriptyline), Beta-Blockers (Metoprolol, Carvedilol, Nebivolol -> bradycardia!), SSRIs, and Risperidone! Griseofulvin is a CYP450 INDUCER: Reduces efficacy of Warfarin (decreases INR!) and Oral Contraceptives (use barrier backup!)

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Check liver tests (LFT) before starting a 4- to 12-week course of Sebifin/Tyza tablets; stop immediately if you develop persistent nausea, dark urine, yellow eyes, loss of taste, or skin rash; for Grisovin FP, take with milk/food and avoid sunlight and alcohol
  • Meal & Clock Timing Instruction: Terbinafine may be taken with or without food; Griseofulvin MUST be taken WITH A HIGH-FAT MEAL or whole milk (doubles GI absorption!) (Once Daily (or BD per specialist protocol))
  • Missed Dose Protocol: Take same day if remembered; do not double dose
  • Geriatric Dispensing Pearl: In older adults with CrCl <50 mL/min or polypharmacy (Metoprolol/Amitriptyline), prefer topical Terbinafine/Luliconazole unless nail/extensive infection requires systemic therapy

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Terbinafine Tablets: 250 mg, 500 mg; Topical Cream: 1%. Griseofulvin Fine-Particle (FP) Microsize Tablets: 125 mg, 250 mg, 500 mg

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.34] (p. 109)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.